First EASL NAFLD Summit: Diagnosis and pharmacotherapy of NASH Radisson Blu ES. Hotel, Via Filippo Turati 171, Rome, 00185, Italy 9-11 November 2017

Description:
NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that lead to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies. As such, the identification and development of new therapies is urgently needed.
This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.

--Who Should Attend:
Basic and translational scientists, Clinical researchers, Industry / Biotechnology, Hepatologists, Health professionals, Regulatory and funding agencies, Young researchers and trainees

Booking: https://go.evvnt.com/125207-1

Price:
EASL Member (VAT exckusive): EUR 450
Non Member (VAT exckusive): EUR 550
Young Investigator and Nurse (EASL Member - VAT exckusive): EUR 150
Young Investigator and Nurse (Non Member - VAT exckusive): EUR 200

Speakers: Prof. Ali Canbay (Germany), Prof. Claus Hellebrand (Germany), Prof. Wing-Kin Syn (United States), Prof. Michael Trauner (Austria)

Time: on Thursday November 09, 2017 at 1:55 pm (ends Saturday November 11, 2017 at 1:45 pm)